NASDAQ:FDMT

4D Molecular Therapeutics Competitors

$33.20
-3.08 (-8.49 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$33.00
Now: $33.20
$36.60
50-Day Range
$34.42
MA: $42.23
$51.39
52-Week Range
$33.97
Now: $33.20
$55.11
Volume66,580 shs
Average Volume161,063 shs
Market Capitalization$886.24 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

4D Molecular Therapeutics (NASDAQ:FDMT) Vs. SEER, NUVB, IBRX, IMCR, BCAB, and CGEM

Should you be buying FDMT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to 4D Molecular Therapeutics, including Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), Immunocore (IMCR), BioAtla (BCAB), and Cullinan Oncology (CGEM).

4D Molecular Therapeutics (NASDAQ:FDMT) and Seer (NASDAQ:SEER) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for 4D Molecular Therapeutics and Seer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4D Molecular Therapeutics01202.67
Seer02202.50

4D Molecular Therapeutics presently has a consensus price target of $45.50, indicating a potential upside of 37.05%. Seer has a consensus price target of $68.00, indicating a potential upside of 33.73%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe 4D Molecular Therapeutics is more favorable than Seer.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and Seer's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular TherapeuticsN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Profitability

This table compares 4D Molecular Therapeutics and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4D Molecular TherapeuticsN/AN/AN/A
SeerN/AN/AN/A

Summary

4D Molecular Therapeutics beats Seer on 2 of the 2 factors compared between the two stocks.

4D Molecular Therapeutics (NASDAQ:FDMT) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for 4D Molecular Therapeutics and Nuvation Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4D Molecular Therapeutics01202.67
Nuvation Bio00603.00

4D Molecular Therapeutics presently has a consensus price target of $45.50, indicating a potential upside of 37.05%. Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 73.48%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Nuvation Bio is more favorable than 4D Molecular Therapeutics.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and Nuvation Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular TherapeuticsN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Profitability

This table compares 4D Molecular Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4D Molecular TherapeuticsN/AN/AN/A
Nuvation BioN/AN/AN/A

Summary

Nuvation Bio beats 4D Molecular Therapeutics on 3 of the 3 factors compared between the two stocks.

4D Molecular Therapeutics (NASDAQ:FDMT) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Profitability

This table compares 4D Molecular Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4D Molecular TherapeuticsN/AN/AN/A
ImmunityBioN/AN/AN/A

Earnings & Valuation

This table compares 4D Molecular Therapeutics and ImmunityBio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular TherapeuticsN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for 4D Molecular Therapeutics and ImmunityBio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4D Molecular Therapeutics01202.67
ImmunityBio00103.00

4D Molecular Therapeutics presently has a consensus price target of $45.50, indicating a potential upside of 37.05%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 43.84%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than 4D Molecular Therapeutics.

Summary

ImmunityBio beats 4D Molecular Therapeutics on 2 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Immunocore and 4D Molecular Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
4D Molecular Therapeutics01202.67

Immunocore presently has a consensus price target of $54.3333, indicating a potential upside of 42.05%. 4D Molecular Therapeutics has a consensus price target of $45.50, indicating a potential upside of 37.05%. Given Immunocore's higher probable upside, equities research analysts plainly believe Immunocore is more favorable than 4D Molecular Therapeutics.

Profitability

This table compares Immunocore and 4D Molecular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
4D Molecular TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Immunocore and 4D Molecular Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
4D Molecular TherapeuticsN/AN/AN/AN/AN/A

Summary

Immunocore beats 4D Molecular Therapeutics on 1 of the 1 factors compared between the two stocks.

4D Molecular Therapeutics (NASDAQ:FDMT) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for 4D Molecular Therapeutics and BioAtla, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4D Molecular Therapeutics01202.67
BioAtla00403.00

4D Molecular Therapeutics presently has a consensus target price of $45.50, indicating a potential upside of 37.05%. BioAtla has a consensus target price of $58.00, indicating a potential upside of 21.49%. Given 4D Molecular Therapeutics' higher possible upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than BioAtla.

Valuation & Earnings

This table compares 4D Molecular Therapeutics and BioAtla's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular TherapeuticsN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Profitability

This table compares 4D Molecular Therapeutics and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4D Molecular TherapeuticsN/AN/AN/A
BioAtlaN/AN/AN/A

Summary

BioAtla beats 4D Molecular Therapeutics on 2 of the 3 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Valuation and Earnings

This table compares Cullinan Oncology and 4D Molecular Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
4D Molecular TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Cullinan Oncology and 4D Molecular Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology01302.75
4D Molecular Therapeutics01202.67

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 37.07%. 4D Molecular Therapeutics has a consensus target price of $45.50, suggesting a potential upside of 37.05%. Given Cullinan Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Cullinan Oncology is more favorable than 4D Molecular Therapeutics.

Profitability

This table compares Cullinan Oncology and 4D Molecular Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
4D Molecular TherapeuticsN/AN/AN/A

Summary

Cullinan Oncology beats 4D Molecular Therapeutics on 3 of the 3 factors compared between the two stocks.


4D Molecular Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SEER
Seer
1.2$50.85-4.2%$3.10 billionN/A0.00Increase in Short Interest
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$10.03-0.4%$2.18 billionN/A0.00Analyst Report
Insider Buying
IBRX
ImmunityBio
1.7$17.38-0.7%$1.90 billionN/A0.00Gap Up
Immunocore logo
IMCR
Immunocore
1.3$38.25-3.0%$1.65 billionN/A0.00Gap Up
BioAtla logo
BCAB
BioAtla
1.5$47.74-0.4%$1.61 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.20-2.0%$1.53 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$37.64-3.5%$1.31 billionN/A0.00Analyst Report
KNTE
Kinnate Biopharma
1.7$29.64-5.2%$1.29 billionN/A0.00Increase in Short Interest
EWTX
Cricut
0.3$27.08-3.1%$1.29 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.03-6.8%$1.29 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Increase in Short Interest
Vor Biopharma logo
VOR
Vor Biopharma
1.9$30.10-4.7%$1.12 billionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.27-0.2%$963.96 millionN/A0.00Analyst Report
Analyst Revision
Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$27.92-0.5%$888.97 millionN/A0.00News Coverage
Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.90-6.9%$845.76 millionN/A0.00
PHAR
Pharming Group
0.0$13.07-3.9%$834.94 millionN/A0.00Decrease in Short Interest
Gap Up
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.36-8.8%$812.29 millionN/A0.00Analyst Report
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.29-3.4%$782.36 millionN/A0.00Analyst Report
Increase in Short Interest
FNCH
Finch Therapeutics Group
2.0$15.99-3.1%$753.85 millionN/A0.00Analyst Report
Analyst Revision
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$15.15-3.6%$615.42 millionN/A0.00
SGTX
Sigilon Therapeutics
1.4$17.04-8.2%$536.64 millionN/A0.00Increase in Short Interest
Inventiva logo
IVA
Inventiva
1.4$13.34-0.5%$515.32 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.24-2.0%$483.31 millionN/A0.00Analyst Report
Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.51-2.1%$461.76 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$17.91-1.1%$449.99 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.12-5.8%$431.90 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.74-12.1%$426.49 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$14.07-5.6%$414.84 millionN/A0.00
PRTG
Portage Biotech
0.0$26.99-7.6%$326.12 millionN/A0.00High Trading Volume
News Coverage
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.34-4.1%$292.09 millionN/A-2.84
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.50-16.2%$276.04 millionN/A-2.57Unusual Options Activity
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.89-8.7%$246.28 millionN/A0.00
LBPH
Longboard Pharmaceuticals
1.9$11.63-7.0%$196.75 millionN/A0.00Analyst Report
Quiet Period Expiration
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$10.10-3.4%$193.10 millionN/A0.00Increase in Short Interest
GANX
Gain Therapeutics
1.7$14.50-2.8%$164.30 millionN/A0.00Analyst Revision
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.55-0.1%$149.71 millionN/A0.00
VINC
Vincerx Pharma
1.0$17.60-4.0%$144.41 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.52-18.4%$125.18 millionN/A0.00Gap Up
LGVN
Longeveron
0.3$6.52-9.5%$123.60 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.87-6.5%$84.17 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$14.76-2.8%$57.68 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.24-3.4%$52.67 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.58-1.1%$46.48 millionN/A0.00News Coverage
Gap Down
VIRX
Viracta Therapeutics
1.7$8.00-0.4%$41.39 millionN/A0.00
VYNT
Vyant Bio
0.0$3.65-0.3%$40.18 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.20-6.3%$37.69 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.55-2.0%$30.99 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$4.36-3.2%$23.39 millionN/A0.00Gap Up
CMMB
Chemomab Therapeutics
0.0$27.26-23.2%$12.65 millionN/A0.00Gap Up
BCTX
BriaCell Therapeutics
0.0$3.26-0.6%$2.52 millionN/A0.00News Coverage
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.57-4.7%$0.00N/A0.00Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.